Skip to Main Content

Angry over the high price of a prostate cancer drug, Baltimore officials have filed a lawsuit accusing a Johnson & Johnson (JNJ) unit of using “sham” patent litigation to delay the availability of lower-cost generics, forcing the city to spend millions of dollars unnecessarily.

The lawsuit alleges that Janssen Biotech and its partner, British Technology Group, undertook a “ruse” when seeking a patent for its Zytiga medicine by failing to disclose certain information to the U.S. Patent and Trademark Office. And the move made it possible for the drug maker to deflect generic rivals longer than it might have otherwise.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.